Русские видео

Сейчас в тренде

Иностранные видео


Скачать с ютуб 237. Reversing Type 2 Diabetes with Sami Inkinen, Founder & CEO of Virta Health в хорошем качестве

237. Reversing Type 2 Diabetes with Sami Inkinen, Founder & CEO of Virta Health 2 недели назад


Если кнопки скачивания не загрузились НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием, пожалуйста напишите в поддержку по адресу внизу страницы.
Спасибо за использование сервиса savevideohd.ru



237. Reversing Type 2 Diabetes with Sami Inkinen, Founder & CEO of Virta Health

Today, I’m joined by Sami Inkinen, founder & CEO of Virta Health. Leading with lifestyle, Virta takes a bottom-up approach to diabetes management. Leveraging ketogenic nutrition therapy, the company is tackling root causes of type 2 diabetes. In this episode, we talk about unwinding the metabolic health crisis. We also cover: • The rise of GLP-1s • Reversing type 2 diabetes • Harms of ultra-processed foods Subscribe to the podcast → insider.fitt.co/podcast Subscribe to our newsletter → insider.fitt.co/subscribe Follow us on LinkedIn → linkedin.com/company/fittinsider Virta Health’s Website: https://www.virtahealth.com/ Virta Health’s YouTube:    / virtahealth   - The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com to learn more about its smart workout solutions for fitness and health facilities. Fitt Talent: https://talent.fitt.co/ Consulting: https://consulting.fitt.co/ Investments: https://capital.fitt.co/ Chapters: (00:00) Introduction (02:01) The ineffectiveness of current diabetes treatment (04:30) Addressing the underlying drivers of diabetes (06:53) Sami’s journey to founding Virta Health (12:47) Virta’s nutritional based approach to solving diabetes (16:24) Operationalizing nutrition therapy (18:26) Business model and sales process (23:01) Incentives and misaligned healthcare (28:08) Default food environment and metabolic health (34:36) The impact of GLP-1 drugs on Virta’s business (40:04) The need for a holistic approach to obesity (41:29) Conclusion

Comments